PetIQ (PETQ) Scheduled to Post Quarterly Earnings on Wednesday

PetIQ (NASDAQ:PETQ) is set to announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.42 per share for the quarter. PetIQ has set its FY 2024 guidance at EPS and its Q1 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

PetIQ (NASDAQ:PETQ) last posted its quarterly earnings data on Wednesday, February 28th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.22. The company had revenue of $219.93 million for the quarter, compared to analysts’ expectations of $189.70 million. PetIQ had a net margin of 0.19% and a return on equity of 11.72%. On average, analysts expect PetIQ to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

PetIQ Stock Up 3.6 %

PETQ stock opened at $17.65 on Tuesday. The company has a current ratio of 2.27, a quick ratio of 1.43 and a debt-to-equity ratio of 1.97. The company’s 50 day moving average is $17.08 and its 200 day moving average is $18.00. The stock has a market cap of $519.44 million, a price-to-earnings ratio of 294.22 and a beta of 1.68. PetIQ has a 1-year low of $11.31 and a 1-year high of $22.98.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group upped their price objective on shares of PetIQ from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. Four analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $29.00.

PetIQ Company Profile

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.